The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...

The pharmaceutical industry is undergoing an era of innovation and change. Over the next few years, companies will need to ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, ...

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...

The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...

Patients with fibrodysplasia ossificans progressiva (FOP) in the US will soon have the option of treatment with another daily ...

Other candidates in its pipeline include injectable GIP/GLP-1 agonist enicepatide, injectable amylin analogue petrelintide, ...